NIAID Advances Entolimod Into Fully Funded GI-ARS Efficacy Study; December Data Readout
VBIO is trading near its 52-week low of $0.616 (3.4% above the low) on light trading volume (0.1× avg).
Summary
NIAID's Radiation and Nuclear Countermeasures Program chose to move Entolimod into a therapeutic efficacy study at the Armed Forces Radiobiology Research Institute, days after positive safety findings. The government pays for the whole study, so Valion spends no cash — critical for a company that reported a $7.1M Q2 net loss with cash down to $2.1M and going concern doubt. The primary endpoint is survival in mice treated 24 hours after radiation exposure, with top-line results expected in early December. A survival benefit would strengthen Entolimod's case as a medical countermeasure under the FDA Animal Rule, where it already holds Fast Track and Orphan Drug designations. This comes as activist 3i, LP holds 46.17% and has been funding the company through preferred tranches, with a $100M shelf and $5M ATM in place. December data is the binary event.
At the time of this announcement, VBIO was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $0.62 to $67.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.